[Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer].
Mitoxantrone (MIT) is a new anthraquinone anticancer agent. We treated 14 patients with locally advanced breast cancer, 3 of which were inflammatory breast cancers, by pre-operative arterial injection of MIT. The treatment protocol was MIT 12 mg/m2 injected into both the internal mammary and the subclavian arteries with oral administration of 5'-DFUR 1,200 mg/day for 20 days. After 2 courses, all tumors were decreased over 50% in size. Down-staging was obtained in all of 8 cases. Mastectomy could be carried out on all patients, without microscopically residual tumor cells. Preoperative arterial injection of MIT might be the treatment of choice for locally advanced breast cancer to perform down-staging, however the survival benefit has remained equivocal. These preliminary results are encouraging to further studies.
Ichikawa
W
W
Second Dept. of Surgery, Tokyo Medical and Dental University.
Osanai
T
T
Shimizu
C
C
Uetake
H
H
Iida
S
S
Yamashita
T
T
Nishi
N
N
Togo
S
S
Miyanaga
T
T
Nihei
Z
Z
Sugihara
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002408:Catheters, Indwelling; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage*
D005467:Floxuridine; D008942:Mitoxantrone; C025034:doxifluridine